These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12193688)

  • 1. Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Okada S; Tokuhisa T; Sakiyama S; Tagawa M
    J Immunol; 2002 Sep; 169(5):2241-5. PubMed ID: 12193688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival.
    Min WP; Gorczynski R; Huang XY; Kushida M; Kim P; Obataki M; Lei J; Suri RM; Cattral MS
    J Immunol; 2000 Jan; 164(1):161-7. PubMed ID: 10605007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
    J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas ligand on tumor cells mediates inactivation of neutrophils.
    Chen YL; Chen SH; Wang JY; Yang BC
    J Immunol; 2003 Aug; 171(3):1183-91. PubMed ID: 12874204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
    Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
    Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
    Hoves S; Krause SW; Halbritter D; Zhang HG; Mountz JD; Schölmerich J; Fleck M
    J Immunol; 2003 Jun; 170(11):5406-13. PubMed ID: 12759415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumocystis cell wall beta-glucans induce dendritic cell costimulatory molecule expression and inflammatory activation through a Fas-Fas ligand mechanism.
    Carmona EM; Vassallo R; Vuk-Pavlovic Z; Standing JE; Kottom TJ; Limper AH
    J Immunol; 2006 Jul; 177(1):459-67. PubMed ID: 16785543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of solid tumor growth by Fas ligand-expressing myoblasts.
    Springer ML; Kraft PE; Blau HM
    Somat Cell Mol Genet; 1998 Sep; 24(5):281-9. PubMed ID: 10696236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
    Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
    Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
    Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of CD4+ T cell apoptosis as a consequence of impaired cytoskeletal rearrangement in UVB-irradiated dendritic cells.
    Wachter T; Averbeck M; Hara H; Tesmann JP; Simon JC; Termeer CC; Denfeld RW
    J Immunol; 2003 Jul; 171(2):776-82. PubMed ID: 12847245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells.
    Yu Y; Hagihara M; Ando K; Gansuvd B; Matsuzawa H; Tsuchiya T; Ueda Y; Inoue H; Hotta T; Kato S
    J Immunol; 2001 Feb; 166(3):1590-600. PubMed ID: 11160200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs.
    Yang R; Xu D; Zhang A; Gruber A
    Int J Cancer; 2001 Nov; 94(3):407-13. PubMed ID: 11745422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts.
    Tourneur L; Malassagne B; Batteux F; Fabre M; Mistou S; Lallemand E; Lores P; Chiocchia G
    J Immunol; 2001 Aug; 167(3):1338-46. PubMed ID: 11466351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection.
    Wolfe T; Asseman C; Hughes A; Matsue H; Takashima A; von Herrath MG
    J Immunol; 2002 Nov; 169(9):4867-72. PubMed ID: 12391197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
    Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.